JP2015502339A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015502339A5 JP2015502339A5 JP2014539018A JP2014539018A JP2015502339A5 JP 2015502339 A5 JP2015502339 A5 JP 2015502339A5 JP 2014539018 A JP2014539018 A JP 2014539018A JP 2014539018 A JP2014539018 A JP 2014539018A JP 2015502339 A5 JP2015502339 A5 JP 2015502339A5
- Authority
- JP
- Japan
- Prior art keywords
- fpsa
- composition
- antibody
- subject
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161551195P | 2011-10-25 | 2011-10-25 | |
| US61/551,195 | 2011-10-25 | ||
| PCT/US2012/061982 WO2013063312A1 (en) | 2011-10-25 | 2012-10-25 | Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016231469A Division JP2017043634A (ja) | 2011-10-25 | 2016-11-29 | 前立腺がんのための診断薬、予後判定薬、および治療薬としてのフリーｐｓａ抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015502339A JP2015502339A (ja) | 2015-01-22 |
| JP2015502339A5 true JP2015502339A5 (enExample) | 2015-12-17 |
| JP6181059B2 JP6181059B2 (ja) | 2017-08-16 |
Family
ID=48168512
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014539018A Active JP6181059B2 (ja) | 2011-10-25 | 2012-10-25 | 前立腺がんのための診断薬、予後判定薬、および治療薬としてのフリーｐｓａ抗体 |
| JP2016231469A Withdrawn JP2017043634A (ja) | 2011-10-25 | 2016-11-29 | 前立腺がんのための診断薬、予後判定薬、および治療薬としてのフリーｐｓａ抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016231469A Withdrawn JP2017043634A (ja) | 2011-10-25 | 2016-11-29 | 前立腺がんのための診断薬、予後判定薬、および治療薬としてのフリーｐｓａ抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20140308204A1 (enExample) |
| EP (1) | EP2771688B1 (enExample) |
| JP (2) | JP6181059B2 (enExample) |
| CN (2) | CN106872702A (enExample) |
| AU (1) | AU2012328679C1 (enExample) |
| CA (1) | CA2853705C (enExample) |
| WO (1) | WO2013063312A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2771688B1 (en) * | 2011-10-25 | 2018-09-26 | Memorial Sloan-Kettering Cancer Center | Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer |
| US10392444B2 (en) | 2014-08-08 | 2019-08-27 | Oncoquest, Inc. | Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer |
| JP6493779B2 (ja) * | 2014-09-19 | 2019-04-03 | 国立大学法人 岡山大学 | ８９Ｚｒの標識方法 |
| WO2017087826A1 (en) * | 2015-11-18 | 2017-05-26 | Memorial Sloan Kettering Cancer Center | Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods |
| IL324632A (en) | 2016-12-01 | 2026-01-01 | Regeneron Pharma | Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging |
| WO2019133797A1 (en) * | 2017-12-29 | 2019-07-04 | Wu, Lester J. | Benzenesulfonamide derivatives and method for modulating lipid raft |
| US20210196779A1 (en) * | 2018-06-01 | 2021-07-01 | Yale University | Compositions and Methods for Treating Steroid Hormone-Related Diseases or Disorders |
| CN108802392A (zh) * | 2018-08-29 | 2018-11-13 | 上海市东方医院 | 一种用于诊断前列腺癌的层析试纸条及其制备方法和应用 |
| CN114324526B (zh) * | 2021-12-27 | 2023-06-27 | 青岛农业大学 | 一种检测人血清中的前列腺特异性抗原的生物传感器及其制备方法和应用 |
| WO2025208344A1 (zh) * | 2024-04-02 | 2025-10-09 | 嘉兴允英医学检验有限公司 | 癌症风险等级预测模型生成和预测的方法和系统 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5171749A (en) | 1987-01-20 | 1992-12-15 | University Of British Columbia | Wavelength-specific cytotoxic agents |
| US5173504A (en) | 1989-04-21 | 1992-12-22 | Health Research, Inc. | Bacteriochlorophyll-a derivatives useful in photodynamic therapy |
| US5171741A (en) | 1989-04-21 | 1992-12-15 | Health Research, Inc. | Bacteriochlorophyll-a derivatives useful in photodynamic therapy |
| US5308608A (en) | 1989-06-07 | 1994-05-03 | University Of British Columbia | Photosensitizing Diels-Alder porphyrin derivatives |
| SE9002480D0 (sv) | 1990-07-23 | 1990-07-23 | Hans Lilja | Assay of free and complexed prostate-specific antigen |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5726304A (en) | 1992-10-30 | 1998-03-10 | The University Of British Columbia | Porphocyanine and CNC-expanded porphyrins |
| US5405957A (en) | 1992-10-30 | 1995-04-11 | The University Of British Columbia | Wavelength-specific photosensitive compounds and expanded porphyrin-like compounds and methods of use |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5648485A (en) | 1994-10-26 | 1997-07-15 | University Of British Columbia | β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins |
| US5773292A (en) | 1995-06-05 | 1998-06-30 | Cornell University | Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood |
| US6379669B1 (en) * | 1995-08-04 | 2002-04-30 | Akhouri A. Sinha | Targeting of organs by immunoconjugates |
| US7659073B2 (en) * | 1997-04-30 | 2010-02-09 | Hybritech Incorporated | Forms of prostate specific antigens and methods for their detection |
| US5880145A (en) | 1997-05-07 | 1999-03-09 | The University Of British Columbia | Class of benzoporphyrin derivative photoactive compounds |
| NZ338031A (en) | 1997-05-07 | 2001-04-27 | Qlt Phototherapeutics Inc | Ethylene glycol esters of monohydrobenzoporphyrin derivatives as photoactive agents and their use in conducting photodynamic diagnosis |
| US6482599B1 (en) * | 1999-04-30 | 2002-11-19 | Hybritech Incorporated | Forms of prostate specific antigen (PSA) specific for benign prostatic hyperplasia (BPH) and methods of using such |
| US6423503B1 (en) * | 1999-04-30 | 2002-07-23 | Hybritech Incorporated | Forms of free prostate-specific antigen (PSA) and their association with prostate tissues from prostate peripheral zone and transition zone |
| FI20002127A0 (fi) * | 2000-09-27 | 2000-09-27 | Artic Partners Oy Ab | Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi |
| US8663600B2 (en) | 2005-02-17 | 2014-03-04 | Diaprost Ab | Diagnosis of prostate cancer |
| US20060199230A1 (en) * | 2005-03-03 | 2006-09-07 | Hybritech Incorporated | Use of prostate specific antigen to predict drug response |
| US20060211059A1 (en) | 2005-03-18 | 2006-09-21 | Taneja Samir S | Methods of improving screening, diagnosis and staging of prostate cancer using serum testosterone |
| WO2010065940A1 (en) * | 2008-12-04 | 2010-06-10 | The Regents Of The University Of California | Materials and methods for determining diagnosis and prognosis of prostate cancer |
| EP2771688B1 (en) | 2011-10-25 | 2018-09-26 | Memorial Sloan-Kettering Cancer Center | Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer |
| WO2017087826A1 (en) | 2015-11-18 | 2017-05-26 | Memorial Sloan Kettering Cancer Center | Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods |
-
2012
- 2012-10-25 EP EP12844178.9A patent/EP2771688B1/en active Active
- 2012-10-25 US US14/353,989 patent/US20140308204A1/en not_active Abandoned
- 2012-10-25 CA CA2853705A patent/CA2853705C/en active Active
- 2012-10-25 WO PCT/US2012/061982 patent/WO2013063312A1/en not_active Ceased
- 2012-10-25 CN CN201611095752.6A patent/CN106872702A/zh active Pending
- 2012-10-25 JP JP2014539018A patent/JP6181059B2/ja active Active
- 2012-10-25 CN CN201280063852.4A patent/CN104040341B/zh active Active
- 2012-10-25 AU AU2012328679A patent/AU2012328679C1/en active Active
-
2016
- 2016-11-29 JP JP2016231469A patent/JP2017043634A/ja not_active Withdrawn
-
2019
- 2019-06-03 US US16/430,041 patent/US11446400B2/en active Active
-
2022
- 2022-08-04 US US17/881,350 patent/US20230040245A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Virgolini et al. | Current status of theranostics in prostate cancer | |
| Chatalic et al. | Towards personalized treatment of prostate cancer: PSMA I&T, a promising prostate-specific membrane antigen-targeted theranostic agent | |
| Rajendran et al. | Imaging hypoxia and angiogenesis in tumors | |
| Ping Li et al. | Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors | |
| Kalidindi et al. | A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals | |
| Gomes et al. | Molecular imaging with SPECT as a tool for drug development | |
| Hohberg et al. | Lacrimal glands may represent organs at risk for radionuclide therapy of prostate cancer with [177Lu] DKFZ-PSMA-617 | |
| Kramer-Marek et al. | The role of nuclear medicine in modern therapy of cancer | |
| Umbricht et al. | Design and preclinical evaluation of an albumin-binding PSMA ligand for 64Cu-based PET imaging | |
| CN112074526B (zh) | 作为治疗性放射性药物的177Lu-DOTA-HYNIC-iPSMA | |
| Galldiks et al. | Applications of PET imaging of neurological tumors with radiolabeled amino acids | |
| Nedrow et al. | Targeting PSMA with a Cu-64 labeled phosphoramidate inhibitor for PET/CT imaging of variant PSMA-expressing xenografts in mouse models of prostate cancer | |
| Pfestroff et al. | Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks | |
| AU2012328679C1 (en) | Free PSA antibodies as diagnostics, prognostics and therapeutics for prostate cancer | |
| Cornelissen et al. | Translational molecular imaging in exocrine pancreatic cancer | |
| Pandit-Taskar et al. | Evaluation of castration-resistant prostate cancer with androgen receptor–axis imaging | |
| Sun et al. | Heterodimeric RGD-NGR PET tracer for the early detection of pancreatic cancer | |
| Liu et al. | [64Cu] Cu-FAP-NOX, a N-oxalyl modified cyclic peptide for FAP PET imaging with a flexible imaging time window | |
| Kong et al. | Managing Lymphoma with Non‐FDG Radiotracers: Current Clinical and Preclinical Applications | |
| Larenkov et al. | Radionuclide diagnosis of prostate cancer: Positron emission tomography with 68Ga-PSMA inhibitors and their pharmaceutical development | |
| Frosina | Non-routine tracers for PET imaging of high-grade glioma | |
| Fang et al. | Advancements in molecular imaging probes for precision diagnosis and treatment of prostate cancer | |
| Osborne et al. | Repeatability of [68Ga] DKFZ11-PSMA PET scans for detecting prostate-specific membrane antigen-positive prostate cancer | |
| JP7309228B2 (ja) | 甲状腺髄様がん標的用組成物 | |
| Marvaso et al. | The current status of novel PET radio-pharmaceuticals in radiotherapy treatment planning of glioma |